Evidence map›Paper›PMID 27075395›Full record

ArticleCancer medicine2016

Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma.

Ci Song, Yao Liu, Lu Xu, Juan Wen, Deke Jiang, Jianguo Chen, Xiangjun Zhai, Zhibin Hu, Li Liu, Jibin Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Ci SongDepartment of Epidemiology, Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Yao LiuPathology Center and Department of Pathology, Soochow University, Suzhou, China.
Lu XuDepartment of Epidemiology, Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Juan WenNanjing Maternity and Child Health Care Institute, Nanjing Maternity and Child Health Care Hospital Affiliated with Nanjing Medical University, Nanjing, China.
Deke JiangState Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China.
Jianguo ChenQidong Liver Cancer Institute, Qidong, China.
Xiangjun ZhaiDepartment of Infection Diseases, Jiangsu Province Center for Disease Prevention and Control, Nanjing, China.
Zhibin HuDepartment of Epidemiology, Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Li LiuDigestive Endoscopy Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jibin LiuDepartment of Hepatobiliary Surgery, Nantong Tumor Hospital, Nantong, China.
Nanjing Medical University · CNFudan University · CNJiangsu Cancer Hospital · CNJiangsu Provincial Center for Disease Control and Prevention · CNNantong Tumor Hospital · CNQidong Liver Cancer Prevention Research · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously we identified that HBV(Hepatitis B virus) sequence variation, which may interact with host human leukocyte antigen (HLA) genetic variation, could influence host risk of hepatocellular carcinoma (HCC). More HBV-host interactions need to be identified. Protein tyrosine phosphatase nonreceptor type 12 (PTPN12), serves as an antagonist to tyrosine kinase signaling, may play integral roles in immune response against HBV infection and the development of HCC. Rs11485985 was an expression quantitative trait loci (eQTL) for PTPN12 by bioinformatics analyses. In this study, we genotyped the PTPN12 eQTL and sequenced the HBV region EnhII/BCP/PC in a case-control cohort including 1507 HBV-related HCC cases and 1560 HBV persistent carriers as controls. The variant genotype GG of rs11489585 increased HCC risk compared to the HBV persistent carriers (adjusted OR = 2.03, 95% confidence interval [CIs] = 1.30-3.18). We also detected borderline significant associations of PTPN12 eQTL rs11489585 with HBV mutations (P = 0.05 for G1799C). Taken together, PTPN12 may influence HCC risk accompanied by HBV mutations.

Indexed as

Gene ExpressionMutationQuantitative Trait LociAllelesCarcinoma, HepatocellularCase-Control StudiesDisease SusceptibilityGenotypeHepatitis BHepatitis B virusHost-Pathogen InteractionsHumansLiver NeoplasmsOdds RatioPolymorphism, Single NucleotideProtein Tyrosine Phosphatase, Non-Receptor Type 12Protein Tyrosine Phosphatase, Non-Receptor Type 12PTPN12 protein, humaneQTLHBV mutationsHCCinteractionPTPN12susceptibility

Identifiers

PMID27075395
PMCPMC4944896
OpenAlexW2338266714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.